Business
AI summaryIRLAB Therapeutics AB discovers and develops drugs for Parkinson's disease and other central nervous system disorders. Its clinical candidates include Mesdopetam (IRL790), which has completed Phase IIb testing for levodopa-induced dyskinesias; Pirepemat (IRL752), in Phase IIB testing for reducing falls in Parkinson's; and IRL757, in Phase I for apathy, along with preclinical programs such as IRL942 and IRL1117 and a discovery project, P003, focused on dopamine receptor agonists. The company was incorporated in 2013 and is headquartered in Gothenburg, Sweden.
